FDA Approves Ibrutinib for Pediatric Patients With Chronic Graft Versus Host Disease, Including A New Oral Suspension

FDA Approves Ibrutinib for Pediatric Patients With Chronic Graft Versus Host Disease, Including A New Oral Suspension

header-info

​The FDA approved ibrutinib for pediatric patients ≥ 1 year of age with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension.